UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination - PubMed (original) (raw)

Comparative Study

. 2005 Nov 3;24(48):7156-69.

doi: 10.1038/sj.onc.1208872.

Affiliations

• PMID: 16170377
• DOI: 10.1038/sj.onc.1208872

Comparative Study

UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination

Mitsuchika Hosoda et al. Oncogene. 2005.

Abstract

p73 protein level is kept extremely low in mammalian cultured cells and its stability may be regulated by not only the ubiquitin/proteasome-dependent proteolysis but also through other unidentified mechanisms. Here, we found for the first time that p73 is physically as well as functionally associated with the U-box-type E3/E4 ubiquitin ligase UFD2a. The immunoprecipitation experiments demonstrated that this interaction is mediated by the COOH-terminal region of p73alpha containing SAM domain. During the cisplatin-induced apoptosis in SH-SY5Y neuroblastoma cells, p73alpha accumulated at a protein level, whereas the endogenous UFD2a was significantly reduced in response to cisplatin. Ectopic expression of UFD2a decreased the half-life of p73alpha in association with a significant inhibition of the p73alpha-mediated transactivation as well as proapoptotic activity. Downregulation of endogenous UFD2a by antisense strategy resulted in a remarkable accumulation of p73alpha. Unexpectedly, UFD2a-mediated degradation of p73alpha was sensitive to the proteasomal inhibitor, however, UFD2a did not affect the ubiquitination levels of p73alpha. Taken together, our present findings imply that UFD2a might promote the proteasomal turnover of p73 in a ubiquitination-independent manner, and also suggest that UFD2a might play an important role in the regulation of cisplatin-induced apoptosis mediated by p73.

Oncogene (2005) 24, 7156-7169. doi:10.1038/sj.onc.1208872; published online 19 September 2005.

PubMed Disclaimer

Similar articles

• NF-kappaB regulates the stability and activity of p73 by inducing its proteolytic degradation through a ubiquitin-dependent proteasome pathway.
  Kikuchi H, Ozaki T, Furuya K, Hanamoto T, Nakanishi M, Yamamoto H, Yoshida K, Todo S, Nakagawara A. Kikuchi H, et al. Oncogene. 2006 Dec 7;25(58):7608-17. doi: 10.1038/sj.onc.1209748. Epub 2006 Sep 4. Oncogene. 2006. PMID: 16953234
• U-box-type ubiquitin E4 ligase, UFD2a attenuates cisplatin mediated degradation of DeltaNp63alpha.
  Chatterjee A, Upadhyay S, Chang X, Nagpal JK, Trink B, Sidransky D. Chatterjee A, et al. Cell Cycle. 2008 May 1;7(9):1231-7. doi: 10.4161/cc.7.9.5795. Epub 2008 Feb 19. Cell Cycle. 2008. PMID: 18418053 Free PMC article.
• Stabilization of p73 by nuclear IkappaB kinase-alpha mediates cisplatin-induced apoptosis.
  Furuya K, Ozaki T, Hanamoto T, Hosoda M, Hayashi S, Barker PA, Takano K, Matsumoto M, Nakagawara A. Furuya K, et al. J Biol Chem. 2007 Jun 22;282(25):18365-18378. doi: 10.1074/jbc.M610522200. Epub 2007 Apr 23. J Biol Chem. 2007. PMID: 17452332
• Functional implication of p73 protein stability in neuronal cell survival and death.
  Ozaki T, Hosoda M, Miyazaki K, Hayashi S, Watanabe K, Nakagawa T, Nakagawara A. Ozaki T, et al. Cancer Lett. 2005 Oct 18;228(1-2):29-35. doi: 10.1016/j.canlet.2004.12.050. Cancer Lett. 2005. PMID: 15907364 Review.
• Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway.
  Bang S, Kaur S, Kurokawa M. Bang S, et al. Int J Mol Sci. 2019 Dec 30;21(1):261. doi: 10.3390/ijms21010261. Int J Mol Sci. 2019. PMID: 31905981 Free PMC article. Review.

Cited by

• The SWIB/MDM2 motif of UBE4B activates the p53 pathway.
  Wu HH, Leng S, Abuetabh Y, Sergi C, Eisenstat DD, Leng R. Wu HH, et al. Mol Ther Nucleic Acids. 2023 Feb 4;31:466-481. doi: 10.1016/j.omtn.2023.02.002. eCollection 2023 Mar 14. Mol Ther Nucleic Acids. 2023. PMID: 36865087 Free PMC article.
• Fine-tuning of mTOR signaling by the UBE4B-KLHL22 E3 ubiquitin ligase cascade in brain development.
  Kong X, Shu X, Wang J, Liu D, Ni Y, Zhao W, Wang L, Gao Z, Chen J, Yang B, Guo X, Wang Z. Kong X, et al. Development. 2022 Dec 15;149(24):dev201286. doi: 10.1242/dev.201286. Epub 2022 Dec 20. Development. 2022. PMID: 36440598 Free PMC article.
• Targeting Post-Translational Modifications of the p73 Protein: A Promising Therapeutic Strategy for Tumors.
  Omran Z, H Dalhat M, Abdullah O, Kaleem M, Hosawi S, A Al-Abbasi F, Wu W, Choudhry H, Alhosin M. Omran Z, et al. Cancers (Basel). 2021 Apr 15;13(8):1916. doi: 10.3390/cancers13081916. Cancers (Basel). 2021. PMID: 33921128 Free PMC article. Review.
• How Is the Fidelity of Proteins Ensured in Terms of Both Quality and Quantity at the Endoplasmic Reticulum? Mechanistic Insights into E3 Ubiquitin Ligases.
  Kang JA, Jeon YJ. Kang JA, et al. Int J Mol Sci. 2021 Feb 19;22(4):2078. doi: 10.3390/ijms22042078. Int J Mol Sci. 2021. PMID: 33669844 Free PMC article. Review.
• Inhibition of tumor suppressor p73 by nerve growth factor receptor via chaperone-mediated autophagy.
  Nguyen D, Yang K, Chiao L, Deng Y, Zhou X, Zhang Z, Zeng SX, Lu H. Nguyen D, et al. J Mol Cell Biol. 2020 Sep 1;12(9):700-712. doi: 10.1093/jmcb/mjaa017. J Mol Cell Biol. 2020. PMID: 32285119 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.